两套化疗方案治疗晚期非小细胞肺癌的临床对比研究

The contrast clinical research of two projects on curing later period NSCLC

目的对比研究长春瑞滨(NVB)联合顺铂(DDP)及吉西他滨(GEM)联合DDP两方案在治疗晚期非小细胞肺癌的临床疗效及毒性反应。方法98例晚期非小细胞肺癌随机分成两组,长春瑞滨(NP)组54例,吉西他滨(GP)组44例,比较两方案疗效。结果NP组完全缓解(CR)2例,部分缓解(PR)20例,有效率40.7%。GP组CR2例,PR16例,有效率40.9%。两组间差异无显著性(P>0.05)。中位生存期(MST):NP组为8.8个月,GP组为9个月,疾病缓解时间(DRT)分别为3.4个月及3.6个月。毒性反应:GP组WBC下降36例,占67%,其中Ⅲ/Ⅳ度白细胞下降10例,占22%,明显高于NP组,(P<0.05);NP组发生静脉炎12例,占22%明显高于GP组,(P<0.05)。结论长春瑞滨联合顺铂与吉西他滨联合顺铂对晚期非小细胞肺癌近期临床疗效、中位生存期及疾病缓解时间相似,毒性反应较轻。因此,两种方案均可作为晚期非小细胞肺癌的一种安全、有效的化疗方案。

Objective To research the clinical effect and toxicity reactionses of NVB united DDP and GEM united DDP on curing the the later period NSCLC. Methods 98 later period NSCLCs were divided into two groups randomly, 54 cases in NP group, 44 cases in GP, the curative effect index differences of the two projects were compared. Results 2 cases in the NP group alleviated （CR） completely, 20 cases alleviated （PR） partly, the efficient rate was 40. 7%. In the GP group, 2 cases alleviatedcompletely, 16 cases alleviated （PR） partly, the efficient rate was 40.9%. The differences between the two groups were not obvious （P 〉 0. 05 ） . An existence period （MST） ： The NP group was 8.8 months, the GP group was 9 months. The disease alleviated time （DRT） to distinguish to 3.4 months and 3.6 months. Toxicity reaction： A WBC descended 36, having 67%, among them, a white cell descends 10, having 22%, obvious and high in NP set, （P 〈 0. 05 ） The NP set takes place the phlebitis12 example, having 22% obvious and high in GP set, （P 〈 0. 05 ）. Conclusion The NVB consociation DDP unites with the GEM the DDP to the NSCLC of the later period in the near future clinical curative effect, medium the existence expect and the disease alleviate time likeness, the toxicity respond lighter. Therefore two kinds of projects all can be NSCLC a kind of safety, valid chemotherapy project of the later period.